Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
Objective to evaluate the efficacy and safety of candonilimab combined with anlotinib in the treatment of progressive or metastatic soft tissue sarcoma that failed previous first-line standard therapy.
Epistemonikos ID: 8a455181da8ecfa444420dad9a32cd69534e5bd8
First added on: May 15, 2024